Analysts Set Cellebrite DI Ltd. (NASDAQ:CLBT) Target Price at $18.57

Cellebrite DI Ltd. (NASDAQ:CLBT) has been assigned a consensus rating of “Buy” from the eight research firms that are presently covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $18.57.

Several equities research analysts recently issued reports on CLBT shares. JPMorgan Chase & Co. upped their price target on Cellebrite DI from $14.00 to $15.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Needham & Company LLC upped their price target on Cellebrite DI from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Bank of America upped their price target on Cellebrite DI from $13.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Deutsche Bank Aktiengesellschaft upped their price target on Cellebrite DI from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Finally, TD Cowen upped their price target on Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Monday, September 23rd.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CLBT. Janney Montgomery Scott LLC grew its stake in Cellebrite DI by 240.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 45,300 shares of the company’s stock valued at $502,000 after purchasing an additional 31,981 shares during the period. Capstone Investment Advisors LLC purchased a new position in shares of Cellebrite DI during the 1st quarter valued at $870,000. GSA Capital Partners LLP lifted its position in shares of Cellebrite DI by 574.0% during the 1st quarter. GSA Capital Partners LLP now owns 286,930 shares of the company’s stock valued at $3,179,000 after buying an additional 244,357 shares during the last quarter. Quantbot Technologies LP lifted its position in shares of Cellebrite DI by 97.7% during the 1st quarter. Quantbot Technologies LP now owns 124,199 shares of the company’s stock valued at $1,376,000 after buying an additional 61,365 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Cellebrite DI by 34.8% during the 1st quarter. SG Americas Securities LLC now owns 51,881 shares of the company’s stock valued at $575,000 after buying an additional 13,392 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Down 0.6 %

Shares of NASDAQ:CLBT opened at $18.36 on Thursday. Cellebrite DI has a twelve month low of $6.55 and a twelve month high of $18.75. The stock’s 50 day moving average is $17.38 and its 200-day moving average is $13.91. The firm has a market capitalization of $3.78 billion, a price-to-earnings ratio of -34.64, a PEG ratio of 2.52 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Thursday, August 15th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. Cellebrite DI had a positive return on equity of 5,902.06% and a negative net margin of 28.51%. The company had revenue of $95.70 million for the quarter, compared to analyst estimates of $91.94 million. During the same period in the prior year, the firm earned $0.05 earnings per share. Cellebrite DI’s revenue for the quarter was up 24.8% on a year-over-year basis. Equities research analysts anticipate that Cellebrite DI will post 0.31 earnings per share for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.